Related Experiment Videos
Periaqueductal gray matter involvement in the muscimol-induced decrease of morphine antinociception
Naunyn-Schmiedeberg'S Archives of Pharmacology
|March 1, 1982
Abstract:
Microinjections of muscimol, a GABA receptor agonist, into the periaqueductal gray matter (PAG) counter-acted the antinociceptive effect of morphine in rats, as measured by the "tail-flick" method. Muscimol's effect was partially reversed by bicuculline.
Insights
GABA receptor agonist muscimol in the periaqueductal gray matter blocked morphine pain relief in rats. Bicuculline partially reversed this effect, indicating GABA
Area of Science:
- Neuroscience
- Pharmacology
- Pain Research
Background:
- The periaqueductal gray matter (PAG) is a key area for pain modulation.
- Morphine is a widely used opioid analgesic.
- GABAergic systems are involved in pain perception and modulation.
Purpose of the Study:
- To investigate the role of GABAergic neurotransmission in the PAG on morphine-induced analgesia.
- To determine if GABA receptor activation in the PAG can counteract morphine's pain-relieving effects.
Main Methods:
- Rats were used as the experimental model.
- Microinjections of muscimol (GABA receptor agonist) were administered into the PAG.
- Antinociceptive effects were measured using the tail-flick test.
- The effect of bicuculline (GABA receptor antagonist) was assessed.
Main Results:
- Microinjection of muscimol into the PAG significantly counteracted the antinociceptive effect of morphine.
- The inhibitory effect of muscimol on morphine analgesia was partially reversed by bicuculline.
- These findings suggest GABAergic pathways in the PAG modulate opioid analgesia.
Conclusions:
- GABAergic neurotransmission within the periaqueductal gray matter plays a crucial role in regulating the efficacy of morphine analgesia.
- Targeting GABA receptors in the PAG could be a strategy to modulate pain perception and opioid effectiveness.